Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience

American Journal of Managed Care

Volumn 9, Issue 5, 2003, Pages 393-400

  Kocs, Darren ^a   Fendrick, A Mark ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ARTICLE; CANCER; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG LABELING; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; NONBIOLOGICAL MODEL; NONHODGKIN LYMPHOMA; ONCOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACADEMIC MEDICAL CENTERS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; DRUG APPROVAL; DRUG COSTS; DRUG LABELING; DRUG UTILIZATION REVIEW; EDUCATION, PHARMACY, CONTINUING; FEMALE; HEALTH SERVICES RESEARCH; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0038182599     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. National Health Statistics Group, Office of the Actuary. National Health Expenditures, 1999. Washington, DC: U.S. Government Printing Office; Summer 2001.
2. Copeland C. Prescription Drugs: Issues of Cost, Coverage, and Quality. EBRI Issue Brief 208. Washington, DC: Employee Benefit Research Institute; April 1999.
3. Chernew M, Smith DG, Kirking DM, Fendrick AM. Decomposing pharmaceutical cost growth in different types of health plans. Am J Manag Care. 2001;7:667-673.
4. Thorpe KE, Knickman JR. Financing for health care. In: Kovner AR, Jonas S, eds. Health Care Delivery in the United States. 6th ed. New York: Springer; 1998:32-63.
5. Thakkar S. Oncologists judge themselves the best judges of cancer treatments. J Natl Cancer Inst. 1997;89:1188-1189.
6. Laetz T, Silberman G. Reimbursement policies constrain the practice of oncology. JAMA. 1991;266:2996-2999.
7. Genentech. Rituxan (rituximab) product information. South San Francisco, Calif: Genentech. Available at: htt://www.gene.com/gene/products/information/oncology/rituxan/index.jsp Last accessed April 12, 2003.
8. Genentech. Rituxan in perspective: First monoclonal antibody in the U.S. remains an innovative force. Available at: http://www.rituxan.com/rituxan/professional/e_product_info/perspective.htm. Accessed December 2, 2002.
9. American Cancer Society. Cancer facts and figures 2001. Available at: http://www.cancer.org/downloads/STT/F&F2001.pdf. Accessed September 14, 2002.
10. Sahyoun NR, Lentzner H, Hoyert D, Robinson KN. Trends in causes of death among the elderly. Aging Trends [serial online]. March 2001;(1):1-10. Available at: http://www.cdc.gov/nchs/data/agingtrends/01death.pdf. Accessed September 14, 2002.
11. U.S. Census Bureau, Population Division. National population projections. I. Summary tables. Available at: http://www.census.gov/population/www/projections/natsum-T3.html. Accessed December 3, 2002.
12. Berk ML, Monheit AC. The concentration of health care expenditures, revisited. Health Aff. 2001;20(2):9-18.
13. Hogan C, Lunney J, Gabel J, et al. Medicare beneficiaries' costs of care in the last year of life. Health Aff. 2001;20(4):188-195.
14. Hearings Before the Subcommittee on Health and the Subcommittee on Oversight and Investigations of the House Committee on Energy and Commerce, 107th Cong, September 21, 2001. Prepared witness testimony of Ezekiel Emanuel, Chief of Clinical Bioethics Department, NIH. Available at: http://energycommerce.house.gov/107/hearings/09212001Hearing371/Emanuel619.htm. Accessed September 14, 2002.
15. Minah K, Blendon RJ, Benson JM. How interested are Americans in new medical technologies? A multicountry comparison. Health Aff. 2001;20(5):194-201.
16. Crawford R. Individual responsibility and health politics. In: Conrad R, Kerns R, eds. The Sociology of Health and Illness, Critical Perspectives. New York: St. Martin's; 1986;484-495.
17. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recently increasing trends. J Natl Cancer Inst. 2001;93:824-842.
18. Fendrick AM, Chernew M, Hirth R, et al. Understanding the behavioral response to medical innovation. Am J Manag Care. 1996;2:793-799.
19. The Kaiser Family Foundation. Prescription drug trends: A chartbook update. November 2001. Available at: http://www.kff.org/content/2001/3112/RxChartbook.pdf. Accessed September 14, 2002.
20. Petersen M. Increased spending on drugs is linked to more advertising. The New York Times. November 21, 2001;C1.
21. The Institute of Medicine. Public confidence and involvement in clinical research: Clinical research roundtable symposium II [summary]. September 25-26, 2000. Available at: http://www.iom.edu/crr. Accessed September 14, 2002.
22. McNeil BJ. Shattuck lecture - Hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345:1612-1620.
23. Landow L. Off-label use of approved drugs. Chest. 1999;116:589-591.
24. Dukes MN. Economic costs of adverse drug reactions. PharmacoEcon. 1992;1:153-154.
25. White TJ Arakelian A, Rho JP. Counting the costs of drug-related adverse events. PharmacoEcon. 1999;15:445:458.
26. National Center for Health Statistics. Health, United States, 2001 with Urban and Rural Health Chartbook. Hyattsville, Md: National Center for Health Statistics; 2001. DHHS Publication 01-1232.
27. Akscin JF. The future of oral chemotherapy drugs. Presented at: 27th Annual National Meeting of the Association of Community Cancer Centers. March 28-31, 2001. Available at: http://www.accc-cancer.org/news/oral/asp. Accessed August 23, 2002.
28. Penchansky R, Thomas JW. The concept of access: Definition and relationship to consumer satisfaction. Med Care. 1981;19:127-140.
29. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
30. Angell M. The pharmaceutical industry - To whom is it accountable? N Engl J Med. 2000;342:1902-1904.
31. Carey J, Barret A. Drug prices: What's fair? December 10, 2001:60-70.
32. Reh M. Changes at FDA may speed drug approval process and increase off-label use. J Natl Cancer Inst. 1998;90:805-807.
33. Weisbrod BA. The health care quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. J Econ Lit. 1991;29:523-552.
34. Freudenheim M, Petersen M. The drug-price express runs into a wall. The New York Times. December 23, 2001:C1.
35. Centers for Medicare and Medicaid Services. Hospital outpatient prospective payment system. Available at http://cms.hhs.gov/regulations/hopps/default.asp. April 23, 2003.
36. Hearings Before the Subcommittee on Health and the Subcommittee on Oversight and Investigations of the House Committee on Energy and Commerce, 107th Cong, September 21, 2001. Prepared witness testimony of William J. Scanlon, Director of Health Care Issues, General Accounting Office. Available at: http://energycommerce.house.gov/107/hearings/09212001Hearing371/Scanlon612.h tm. Accessed August 23, 2002.
37. United States General Accounting Office. Medicare: Payments for covered outpatient drugs exceed providers' cost. September 2001. Publication GAO 01-1118. Available at http://www.gao/gov/new.items/d01118.pdf. Accessed April 12, 2003.
38. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861-867. Accessed August 23, 2002.
39. Atkins CD. Ethics of off-label treatment. J Clin Oncol. 1998;16:1637.
40. Oldenburg B, Hardcastle D, Kok G. Diffusion of innovations. In: Glanz K, Lewis FM, Rimer B, eds. Health Behavior and Health Education. San Francisco, Calif: Jossey-Bass; 1997:270-286.
41. Wyszewianski L, Green LA. Strategies for changing clinician's practice patterns: A new perspective. J Fam Pract. 2000;49;461-464.
42. Fendrick AM, Schwartz JS. Physician's decisions regarding the acquisition of technology. In: Gelijns AC, Dawkins HV, eds. Medical Innovations at the Crossroads, Vol. 4, Adopting New Medical Technology. Washington, DC: National Academy Press; 1994;71-84.
43. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clinical Oncology. 1999;17(6):1851-1857.
44. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment. J Clinical Oncology. 2000;18(17):3135-3143.